Recently, immune checkpoint blockade with programmed death 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors was demonstrated to be efficacious for lung cancer patients [26], and PD-L1 expression on tumor tissues could be a predictive biomarker of clinical benefit in NSCLC patients. Here, CD274 is linked to neoplasm.